| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
This compound does not have a specific biological target, though it has been shown to inhibit enzymes and signaling pathways involved in inflammation, cell proliferation, and viral replication. Its primary use is as a chemical reagent. It can act as a reducing agent and a source of the diboron moiety in borylation reactions.
|
|---|---|
| ln Vitro |
In vitro, this compound has demonstrated anti-inflammatory, anti-cancer, and anti-viral properties. Its mechanism of action involves the inhibition of enzymes and signaling pathways that are involved in these processes. However, it is primarily used as a chemical reagent rather than a therapeutic agent.
|
| ln Vivo |
This compound has shown in vivo activity in preclinical models, exhibiting anti-inflammatory, anti-cancer, and anti-viral properties. However, detailed in vivo studies are limited as its primary use is as a chemical reagent. It may be used in the synthesis of boron-containing drugs that are later tested in animals.
|
| Enzyme Assay |
Non-cellular enzyme assays could be used to study its mechanism of action. For example, its inhibition of specific enzymes involved in inflammation or viral replication could be measured in vitro using purified enzymes and appropriate substrates. However, this is not a standard application, as it is primarily a chemical reagent.
|
| Cell Assay |
This compound is not typically used in cell-based assays as a therapeutic agent. Its role is as a chemical reagent in synthesis. It may be used to synthesize boron-containing compounds that are then tested in cells. It is soluble in methanol and should be kept in a dark, dry place.
|
| Animal Protocol |
In vivo animal experiments may be conducted to study the anti-inflammatory, anti-cancer, or anti-viral properties of this compound, but it is not a standard therapeutic agent. It is more commonly used as a reagent to synthesize other compounds. Its safety and efficacy in animals are not well-characterized for therapeutic use.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not well-documented as this is not a drug. It is a small molecule (MW 89.65) that is a solid at room temperature. It is sensitive to air and moisture and should be stored in a sealed, dry environment at room temperature or below 15°C.
|
| Toxicity/Toxicokinetics |
The toxicity of Tetrahydroxydiboron is not extensively documented. As a boron-containing compound, it should be handled with care. Standard laboratory safety practices should be followed. It is not intended for human or veterinary use. Specific LD50 values are not typically reported for this reagent.
|
| Additional Infomation |
Hypoboronic acid is a boron oxyacid, an inorganic acid derived from the hydride of diborane (4).
Tetrahydroxydiboron is a versatile reagent in organic synthesis, used in various borylation and coupling reactions. Its potential biological activities have been noted, but it is primarily a research chemical. It is not a pharmaceutical and has no clinical trials or approved therapeutic status. |
| Molecular Formula |
B2H4O4
|
|---|---|
| Molecular Weight |
89.65
|
| Exact Mass |
90.029
|
| CAS # |
13675-18-8
|
| PubChem CID |
10986154
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Melting Point |
290°C(lit.)
|
| Index of Refraction |
1.397
|
| LogP |
-0.16
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
6
|
| Complexity |
26.5
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
B(B(O)O)(O)O
|
| InChi Key |
SKOWZLGOFVSKLB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/B2H4O4/c3-1(4)2(5)6/h3-6H
|
| Chemical Name |
hypoboric acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (1115.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (27.89 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (27.89 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (27.89 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 11.1545 mL | 55.7724 mL | 111.5449 mL | |
| 5 mM | 2.2309 mL | 11.1545 mL | 22.3090 mL | |
| 10 mM | 1.1154 mL | 5.5772 mL | 11.1545 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
